Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals Ltd India has signed an in-licensing agreement with Italian biotechnology company Lay Line Genomics for the entire intellectual property related to developing a biological pain molecule, BXL1H5.
Subscribe to our email newsletter
BXL1H5 is a novel monoclonal antibody that binds to TrkA receptors or targets used in developing treatments to tackle pain.
The license for the process involving TrkA receptors has been granted to Glenmark’s wholly owned subsidiary Glenmark Pharmaceuticals SA (GPSA), the company said.
As part of the agreement, Glenmark will further develop and commercialise BXL1H5 in exchange for an undisclosed upfront and milestone payments to Lay Line Genomics.
The India-based drug maker plans to develop BXL1H5 at its biologics research centre in Switzerland, which focuses on discovering and developing novel biologic entities (NBE).
Glenmark CEO and MD Glenn Saldanha said that the drug firm will leverage its expertise in monoclonal antibodies to progress BXL1H5 rapidly into clinical development.